Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Bladder Dysfunction Reports
Published in: Current Bladder Dysfunction Reports 4/2023

02-10-2023 | Pain Syndromes

Role of Onabotulinum Toxin-A Injection in the Management of Pain and Sexual Dysfunction in Women with BPS/IC

Authors: Murat Can Karaburun, Ömer Gülpınar

Published in: Current Bladder Dysfunction Reports | Issue 4/2023

Login to get access

Abstract

Purpose of Review

In this review, we aimed to summarize the effects of BoNT-A injections on pain and sexual dysfunction in women with BPS/IC in the light of current literature.

Recent Findings

In recent years, randomized controlled studies have provided evidence for the positive effects of intravesical BoNT-A treatment on pain and quality of life scores in patients with BPS/IC. Trigonal injections have demonstrated similar efficacy and safety to those administered to the bladder body. Furthermore, noninvasive alternatives such as low-energy shock wave plus intravesical instillation, hydrogel-based instillation, and liposome-encapsulated BoNT-A instillations have been explored for patients with BPS/IC. The studies examining the impact of BoNT-A on sexual functions are limited. Only one published study has shown improvement in sexual functions with intravesical BoNT-A.

Summary

Intravesical BoNT-A treatment in BPS/IC patients is an effective and safe method recommended by the guidelines. In the light of current literature, this treatment also provides an improvement in sexual functions.
Literature
1.
Engeler D, Baranowski A, Borovicka J. EAU guidelines on chronic pelvic pain. Copenhagen: EAU Guidelines. in EAU Annual Congress; 2018.
2.
Hanno PM, et al. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193(5):1545–53.CrossRefPubMed
3.
Engeler DS, et al. The 2013 EAU guidelines on chronic pelvic pain: is management of chronic pelvic pain a habit, a philosophy, or a science? 10 years of development. Eur Urol. 2013;64(3):431–9.CrossRefPubMed
4.
Bogart LM, et al. Prevalence and correlates of sexual dysfunction among women with bladder pain syndrome/interstitial cystitis. Urology. 2011;77(3):576–80.CrossRefPubMed
5.
Giannantoni A, et al. Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup. J Urol. 2008;179(3):1031–4.CrossRefPubMed
6.
Sacco E, et al. Bladder pain syndrome associated with highest impact on sexual function among women with lower urinary tract symptoms. Int J Gynaecol Obstet. 2012;117(2):168–72.CrossRefPubMed
7.
Okui N, Okui M, Gambacciani M. Examining vaginal and vulvar health and sexual dysfunction in patients with interstitial cystitis (UNICORN-1 study). Int Urogynecol J. 2022;33(9):2493–9.CrossRefPubMed
8.
Gupta P, et al. A multidisciplinary approach to the evaluation and management of interstitial cystitis/bladder pain syndrome: an ideal model of care. Transl Androl Urol. 2015;4(6):611–9.PubMedPubMedCentral
9.
Peters KM, et al. Sexual function and sexual distress in women with interstitial cystitis: a case-control study. Urology. 2007;70(3):543–7.CrossRefPubMed
10.
Carrico DJ, Sherer KL, Peters KM. The relationship of interstitial cystitis/painful bladder syndrome to vulvodynia. Urol Nurs. 2009;29(4):233–8.PubMed
11.
Dykstra DD, et al. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988;139(5):919–22.CrossRefPubMed
12.
Schurch B, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164(3 Pt 1):692–7.CrossRefPubMed
13.
Schulte-Baukloh H, et al. Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology. 2005;66(1):82–7.CrossRefPubMed
14.
Smith CP, et al. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology. 2004;64(5):871–5 (discussion 875).CrossRefPubMed
15.
Zhang W, et al. Intravesical treatment for interstitial cystitis/painful bladder syndrome: a network meta-analysis. Int Urogynecol J. 2017;28(4):515–25.CrossRefPubMed
16.
Brown EA, Schütz SG, Simpson DM. Botulinum toxin for neuropathic pain and spasticity: an overview. Pain Manag. 2014;4(2):129–51.CrossRefPubMed
17.
Park J, Park HJ. Botulinum toxin for the treatment of neuropathic pain. Toxins (Basel). 2017;9(9):260.CrossRefPubMed
18.
Lagueny A, Burbaud P. Mechanism of action, clinical indication and results of treatment of botulinum toxin. Neurophysiol Clin. 1996;26(4):216–26.CrossRefPubMed
19.
Chen JL, Kuo HC. Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis. Investig Clin Urol. 2020;61(Suppl 1):S33-s42.CrossRefPubMed
20.
Lucioni A, et al. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 2008;101(3):366–70.CrossRefPubMed
21.
Yiangou Y, et al. Capsaicin receptor VR1 and ATP-gated ion channel P2X3 in human urinary bladder. BJU Int. 2001;87(9):774–9.CrossRefPubMed
22.
Guo BL, et al. A closer look to botulinum neurotoxin type A-induced analgesia. Toxicon. 2013;71:134–9.CrossRefPubMed
23.
Chiu B, et al. Botulinum toxin A for bladder pain syndrome/interstitial cystitis. Toxins (Basel). 2016;8(7):201.CrossRefPubMed
24.
Sengupta JN. Visceral pain: the neurophysiological mechanism. Handb Exp Pharmacol. 2009;194:31–74.CrossRef
25.
Jhang JF. Using botulinum toxin A for treatment of interstitial cystitis/bladder pain syndrome-possible pathomechanisms and practical issues. Toxins (Basel). 2019;11(11):641.CrossRefPubMed
26.
Jhang JF, Kuo HC. Novel applications of onabotulinum toxin A in lower urinary tract dysfunction. Toxins (Basel). 2018;10(7):260.CrossRefPubMed
27.
Yosef A, et al. Multifactorial contributors to the severity of chronic pelvic pain in women. Am J Obstet Gynecol. 2016;215(6):760.e1-760.e14.CrossRefPubMed
28.
29.
•• Jiang YH, et al. Comparative study of efficacy and safety between bladder body and trigonal intravesical onabotulinum toxin A injection in the treatment of interstitial cystitis refractory to conventional treatment-a prospective, randomized, clinical trial. Neurourol Urodyn. 2018;37(4):1467–73. This trial compared the injection locations.CrossRefPubMed
30.
•• Evans RJ, et al. Injection location does not impact botulinum toxin A efficacy in interstitial cystitis/bladder pain syndrome patients. Can J Urol. 2020;27(1):10125–9. This trial compared the injection locations.PubMed
31.
•• Pinto RA, et al. Intratrigonal onabotulinum toxin A improves bladder symptoms and quality of life in patients with bladder pain syndrome/interstitial cystitis: a pilot, single center, randomized, double-blind, placebo controlled trial. J Urol. 2018;199(4):998–1003. This trial showed the efficacy of trigonal injections.CrossRefPubMed
32.
Jhang JF, Kuo HC. Novel applications of non-invasive intravesical botulinum toxin a delivery in the treatment of functional bladder disorders. Toxins (Basel). 2021;13(5):359.CrossRefPubMed
33.
Chuang YC, Kuo HC. A prospective, multicenter, double-blind, randomized trial of bladder instillation of liposome formulation onabotulinum toxin A for interstitial cystitis/bladder pain syndrome. J Urol. 2017;198(2):376–82.CrossRefPubMed
34.
Rappaport YH, et al. Safety and feasibility of intravesical instillation of botulinum toxin-A in hydrogel-based slow-release delivery system in patients with interstitial cystitis-bladder pain syndrome: a pilot study. Urology. 2018;114:60–5.CrossRefPubMed
35.
36.
Jiang YH, et al. Low-energy shock wave plus intravesical instillation of botulinum toxin A for interstitial cystitis/bladder pain syndrome: pathophysiology and preliminary result of a novel minimally invasive treatment. Biomedicines. 2022;10(2):396.CrossRefPubMedPubMedCentral
37.
•• Chen A, Shahiyan RH, Anger JT. Interstitial cystitis/bladder pain syndrome treatment: a systematic review of sexual health outcomes. Sex Med Rev. 2022;10(1):71–6. This review focused on the sexual health outcomes of Interstitial cystitis/Bladder pain syndrome.CrossRefPubMed
38.
•• Topcuoglu M, et al. Sexual dysfunction in women with interstitial cystitis/bladder pain syndrome: do onabotulinum toxin-A injections improve sexual function? Neurourol Urodyn. 2023;42(3):607–14. This is the first study investigating BoNT-A effects on sexual functions in patients with IC/BPS.CrossRefPubMed
39.
Balzarro M, et al. Onabotulinum toxin A detrusor injection improves female sexual function in women with overactive bladder wet syndrome. Eur J Obstet Gynecol Reprod Biol. 2018;225:228–31.CrossRefPubMed
40.
Shawer S, et al. Impact of intravesical onabotulinum toxin A (Botox) on sexual function in patients with overactive bladder syndrome: a systematic review and meta-analysis. Int Urogynecol J. 2022;33(2):235–43.PubMed
Metadata
Title
Role of Onabotulinum Toxin-A Injection in the Management of Pain and Sexual Dysfunction in Women with BPS/IC
Authors
Murat Can Karaburun
Ömer Gülpınar
Publication date
02-10-2023
Publisher
Springer US
Published in
Current Bladder Dysfunction Reports / Issue 4/2023
Print ISSN: 1931-7212
Electronic ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-023-00715-5

Other articles of this Issue 4/2023

Current Bladder Dysfunction Reports 4/2023 Go to the issue

Review

Botulinumtoxin Injection Versus Augmentation Cystoplasty for Neurogenic Bladder: Where Do We Stand?

Review

Management of Urgency Urinary Incontinence After Orthotopic Neobladder

ReviewPaper

Cutaneous Vesicostomy: Patient Selection, Techniques, Outcomes, and Management

ReviewPaper

Imaging in Pelvic Organ Prolapse — When Should It Be Routine?

ReviewPaper

The Role of Physical Therapy in the Treatment of Pediatric Bladder Dysfunction

ReviewPaper

Management of Patients with Detrusor Hyperactivity with Impaired Contractility